RGX‐202 (NCT05693142) is designed for DMD patients aged 4–11 years and employs the AAV8 vector to deliver the transgene that encodes a novel microdystrophin which incorporates the functional C‐terminal (CT) domain of naturally occurring dystrophin. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.